文献速递浆细胞疾病造血干细胞移植与细胞治疗

新诊断骨髓瘤患者自体造血干细胞移植后接受卡非佐米、来那度胺和地塞米松或来那度胺单药维持治疗的多克隆免疫球蛋白恢复:随机3期ATLAS试验的子分析

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
PubMed 文献 · Br J Haematol · 2023-09-10

ATLAS试验随机180例新诊断骨髓瘤患者,比较卡非佐米、来那度胺、地塞米松(KRd)与来那度胺(R)维持治疗。维持治疗启动后1年,R组(58/66,p<0.001)及KRd降阶梯至R组(27/38,p<0.001)至少部分多克隆免疫球蛋白恢复的患者均多于KRd组(9/36)。至少部分免疫球蛋白恢复与未恢复患者无进展生存期无差异。

要点

  • 维持治疗1年时R组多克隆免疫球蛋白至少部分恢复比例高于KRd组。
  • KRd降阶梯至R组恢复比例亦高于持续KRd组。
  • 多克隆免疫球蛋白恢复与未恢复患者无进展生存期无差异。

核心结论

  • 移植后接受持续治疗的患者存在 prolonged 免疫麻痹,限制了多克隆免疫球蛋白恢复在此背景下的预后意义。

研究设计与样本

  • 随机3期ATLAS试验的子分析,纳入180例受试者,随机分配至卡非佐米、来那度胺、地塞米松(KRd)或来那度胺(R)维持治疗。
  • KRd组中,6周期后微小残留病阴性的标危患者在8周期后降阶梯至来那度胺单药。
  • 对多克隆免疫球蛋白浓度及独特B细胞序列进行纵向分析。

主要发现

  • 维持治疗启动后1年,R组至少部分多克隆免疫球蛋白恢复58/66(p<0.001),KRd降阶梯至R组27/38(p<0.001),均高于KRd组9/36。
  • 从KRd转换为R的患者,未受累免疫球蛋白浓度及B细胞独特序列数随时间增加,接近R组观察值。
  • 至少部分免疫球蛋白恢复患者与其余人群的无进展生存期无差异。

临床怎么用

  • 原文结论指出持续治疗患者存在 prolonged 免疫麻痹,限制多克隆免疫球蛋白恢复的预后意义,未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous studies suggest that postautologous stem cell transplant (ASCT) recovery of polyclonal immunoglobulin from immunoparesis in patients with multiple myeloma is a positive prognostic marker. We performed a longitudinal analysis of polyclonal immunoglobulin concentrations and unique B-cell sequences in patients enrolled in the phase 3 ATLAS trial that randomized 180 subjects to either carfilzomib, lenalidomide, dexamethasone (KRd) or lenalidomide (R) maintenance. In the KRd arm, standard-risk patients with minimal residual disease negativity after six cycles de-escalated to R alone after cycle 8. One year from the initiation of maintenance at least partial recovery of polyclonal immunoglobulin was observed in more patients on the R arm (58/66, p < 0.001) and in those who de-escalated from KRd to R (27/38, p < 0.001) compared to the KRd arm (9/36). In patients who switched from KRd to R, the concentrations of uninvolved immunoglobulin and the number of B-cell unique sequences increased over time, approaching values observed in the R arm. There were no differences in progression-free survival between the patients with at least partial immunoglobulin recovery and the remaining population. Our analysis indicates that patients receiving continuous therapy after ASCT experience prolonged immunoparesis, limiting prognostic significance of polyclonal immunoglobulin recovery in this setting.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kubicki T, Dytfeld D, Wróbel T, et al. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023. PMID: 37691005. doi:10.1111/bjh.19097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。